ioversol (optiray) Report issue

Small molecule Imaging Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Ioversol is an organoiodine compound that used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is indicated in adults for peripheral and coronary arteriography and left ventriculography, for excretory urography and computed tomography. Injections of contrast media are often associated with sensations of warmth and pain. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents.   NCATS

Chemistry

  • SMILES: OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
  • InChIKey: AMDBBAQNWSUWGN-UHFFFAOYSA-N
  • Mol. Mass: 807.1113
  • ALogP: -2.02
  • ChEMBL Molecule:
    ioversol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.2881 - $17.7325
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ioversol | joversol | mp-328 | n,n'-bis (2,3-dihydroxypropyl)-5-[n-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide | optiray | optiray | optiray 160 | optiray 240 | optiray 300 | optiray 320 | optiray 350

Organizations (12)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (3)


 

Cardiovascular Diseases (approved 1988)

Glioma (approved 1988)

Urologic Diseases (approved 1988)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Breast Neoplasms (Phase 4)

Coronary Artery Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Hypothyroidism (Phase 4)

Kidney Failure, Chronic (Phase 4)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Early Phase 1)

Leukemia, Myeloid, Acute (Early Phase 1)

Multiple Myeloma (Early Phase 1)

Myelodysplastic Syndromes (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue